Core Viewpoint - The company Jianfa Zhixin (301584) has announced its earnings forecast for the year 2025, projecting a net profit attributable to shareholders of between 242 million and 296 million yuan, representing a year-on-year growth of 6.00% to 29.65% [1] Summary by Category - **Earnings Forecast** - The company expects a net profit for 2025 to be in the range of 242 million to 296 million yuan [1] - This forecast indicates a growth rate between 6.00% and 29.65% compared to the previous year [1]

Core Viewpoint - The company Jianfa Zhixin expects a net profit attributable to shareholders of 242 million to 296 million yuan for 2025, representing a year-on-year growth of 6% to 29.65% due to the rapid development of its medical consumables centralized operation (SPD) business, which has a high gross profit margin [1] Group 1 - The company's SPD business is experiencing rapid growth, contributing significantly to overall profitability [1] - The gross profit margin of the SPD business is high, enhancing the company's overall profitability [1] - The company is optimizing its financial structure, resulting in a year-on-year decrease in interest-bearing liabilities [1] Group 2 - The company has engaged in communication and negotiation with financial institutions to reduce financing costs, positively impacting net profit [1] - Financial expenses have decreased year-on-year, further contributing to the increase in net profit [1]

证券代码：301584 证券简称：建发致新 公告编号：2026-002 | 项目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | 盈利：24,200 | 万元—29,600 | 万元 | 盈利：22,831.16 | 万 | | | 比上年同期增长：6.00%—29.65% | | | 元 | | | 归属于上市公司股东的扣除非 | 盈利：23,200 | 万元—28,600 | 万元 | 盈利：22,356.54 | 万 | | 经常性损益后的净利润 | | | | 元 | | | | 比上年同期增长：3.77%—27.93% | | | | | 二、与会计师事务所沟通情况 本次业绩预告的相关数据是公司财务部门初步测算结果，未经审计机构审计。 公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与 会计师事务所在本报告期的业绩预告方面不存在分歧。 三、业绩变动原因说明 上海建发致新医疗科技集团股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 ...

Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. held its first extraordinary shareholders' meeting on January 13, 2026, where two proposals were passed with over 99.9% support, indicating strong shareholder confidence in the company's strategic direction and governance structure [1][5]. Group 1: Meeting Attendance - The shareholders' meeting was convened by the board of directors and took place at Shanghai Jianda International Building, with a total of 238 shareholders present, representing 358,313,764 shares, which is 85.0519% of the total voting shares [2]. - Among the attendees, 3 shareholders voted in person, representing 182,698,512 shares (43.3666%), while 235 shareholders participated via online voting, representing 175,615,252 shares (41.6853%) [2]. - Small shareholders accounted for 30,692,452 shares, which is 7.2854% of the total voting shares [2]. Group 2: Proposal Voting Results - Proposal 1: The adjustment of the implementation subjects for certain fundraising investment projects received 358,256,764 votes in favor, accounting for 99.9841% of the valid votes [3]. - Small shareholders voted 30,635,452 shares in favor of Proposal 1, representing 99.8143% of the small shareholders' valid votes [3]. - Proposal 2: The establishment of a remuneration management system for directors and senior management garnered 358,244,864 votes in favor, which is 99.9808% of the valid votes [3]. - Small shareholders supported Proposal 2 with 30,623,552 votes in favor, representing 99.7755% of their valid votes [3]. Group 3: Legal Opinion - The meeting was witnessed by lawyers from Beijing Guofeng Law Firm, who confirmed that the convening and procedures of the meeting complied with legal and regulatory requirements, ensuring the legitimacy of the meeting and voting results [4]. Group 4: Implications of the Meeting - The successful convening of the shareholders' meeting and the high approval rates for the proposals reflect shareholders' strong recognition of the company's strategic development and governance structure, laying a solid foundation for the advancement of future fundraising projects and standardized management [5].

特别提示： 1.本次股东会不存在否决议案的情形。 证券代码：301584 证券简称：建发致新 公告编号：2026-001 上海建发致新医疗科技集团股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.召集人：公司董事会 2.会议时间： （1）现场会议时间：2026年1月13日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026年1月13日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为2026年1月13日9:15至15:00的任意时间。 3.会议地点：上海市杨浦区秦皇岛路32号上海建发国际大厦9楼1号会议室 4.召开方式：现场表决与网络投票相结合。 1 5.现场会议主持人：董事长余峰先生 1.股东出席总体情况： 通过现场和网络投票的股东238人，代表股份358,313,764股，占公司有表决 权股份总数的85.0519 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于上海建发致新医疗科技集团股份有限公司 2026 年第一次临时股东会的 法律意见书 国枫律股字[2026]A0011 号 致：上海建发致新医疗科技集团股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2026 年第一次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《上海建发致新医疗 科技集团股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集 与召开程序、召集人资格、出席会议人员资格、会议 ...

证券之星消息，1月13日医药商业板块较上一交易日上涨1.21%，漱玉平民领涨。当日上证指数报收于 4138.76，下跌0.64%。深证成指报收于14169.4，下跌1.37%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301017 | 漱玉平民 | 19.43 | 10.15% | 54.42万 | | 10.29 乙 | | 002589 | 瑞康医药 | 3.83 | 10.06% | 249.39万 | | 9.08亿 | | 000078 | 海王生物 | 4.08 | 9.97% | 279.00万 | | 10.88 Z | | 301408 | 华人健康 | 24.80 | 7.83% | 60.58万 | | 15.16亿 | | 301584 | 建发致新 | 32.75 | 5.58% | 15.72万 | | 5.08亿 | | 300937 | 药易购 | 40.41 | 5.18% | 18.39万 | | 7.49亿 ...

证券日报网讯1月12日，建发致新（301584）在互动平台回答投资者提问时表示，公司的估值由资本市 场投资者基于公司经营情况等因素确定，公司尊重资本市场的定价有效性，公司将一如既往努力经营， 以更好的经营业绩反馈投资者。 ...

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

证券日报网讯1月9日，建发致新（301584）在互动平台回答投资者提问时表示，上市公司股价受市场、 行业、经营和交易情绪等多种因素影响，公司目前经营正常，不存在未及时披露信息情形。 ...